Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Sep 22, 2016 • 9:00 AM EDT
Ligand Licenses Four Programs to Seelos Therapeutics
Sep 16, 2016 • 9:00 AM EDT
Ligand Enters OmniAb® License Agreement with TeneoBio, Inc.
Sep 13, 2016 • 8:30 AM EDT
Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes
Sep 13, 2016 • 9:10am EDT
New York City
See all events
Sep 12, 2016 • 9:55am EDT
Aug 4, 2016 • 9:00am EDT
Lubricin data demonstrates significant improvement in dry eye disease compared to sodium hyaluronate https://t.co/PqEWkkzgW6
$Sage will present additional data on SAGE-547 in SRSE in 5 abstracts at NCS meeting @neurocritical #biotech #CNS https://t.co/Ud14xnUQp5
SAGE announces publication highlighting epidemiology and burden of illness for SRSE in Journal of Medical Economics https://t.co/TjWymGcxSr